Stratasys (SSYS) Launches Compact Medical 3D Printer J5 MediJet

Stratasys SSYS recently introduced a compact medical 3D printer — Stratasys J5 MediJet — that integrates multiple applications into one system, enabling users to create intricate 3D anatomical models.

Notably, the J5 MediJet 3D printer is up to 30% faster than other 3D printers.

Osnat Philipp, Healthcare vice president at Stratasys, said, “For small to midsized hospitals, we’re enabling access to models and guides with a medical-specific 3D printer that is office-friendly and affordable, while ensuring sterilization is easy so you can bring models right into the operating room with you.”

Stratasys, Ltd. Price and Consensus


Stratasys, Ltd. Price and Consensus

Stratasys, Ltd. price-consensus-chart | Stratasys, Ltd. Quote


Stratasys believes that the J5 MediJet printer can help medical device companies innovate technologies faster by providing models for benchmark testing of medical devices.

Stratasys launched several innovative products that positioned the company well over the long term. Stratasys’ machines facilitate prototyping within a few hours, which reduces development time and upfront costs.

In March, Stratasys launched its new compact multi-material dental 3D printer — J5 DentaJet — to eliminate the time-consuming process of producing dental parts.

Markedly. the 3D printing market presents a favorable long-term investment opportunity as a large number of engineers, designers, architects and entrepreneurs are resorting to 3D solutions for their primary designing and product modeling. Per Statista, the global 3D printing market is expected to reach $40.8 billion by 2024, representing a CAGR of 26% through 2022-2024. As the industry leader in 3D printing, this is encouraging information for Stratasys as it will be able to grab a large share of this market.

The bright prospects of the dental 3D printing space are attracting tough competition from 3D printing stalwarts like HP HPQ, 3D Systems DDD and Voxeljet VJET. Nonetheless, with the recent buyout of Origin, Stratasys gains a competitive edge in the 3D-printed mass production parts market with the integration of the former’s software-centric additive manufacturing solution. Moreover, Origin’s manufacturing-grade 3D printer, which uses its proprietary resin-based Programmable PhotoPolymerization (P3) technology, is expected to enable Stratasys to deliver polymer-based additive systems to dental, medical, tooling and other industries. This will help the company generate incremental annual revenues of $200 million within five years.

Stratasys currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report

HP Inc. (HPQ): Free Stock Analysis Report

Stratasys, Ltd. (SSYS): Free Stock Analysis Report

3D Systems Corporation (DDD): Free Stock Analysis Report

voxeljet AG (VJET): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Stocks Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More